CLEAR Outcomes

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Patient / Population Intervention / Exposure Comparison Outcome

In 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.

13,970

Design

Double-blind RCT

Endpoint

CV death, MI, stroke or coronary revascularisation

Relevance

Result11.7 % vs 13.3 % (HR 0.87); no new-onset diabetes; gout and tendon-rupture signals.

Nissen SE, et al. N Engl J Med. 2023;388(15):1353-1364. 10.1056/NEJMoa2215024

Discussion & critique

Provides an outcomes-proven non-statin oral option for the genuinely statin-intolerant. The effect size is modest; the primary-prevention subgroup did better.